Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan clinical oncology group trial (JCOG9802)

Annals of Oncology

Volumn 20, Issue 7, 2009, Pages 1210-1215

  Katsumata, N ^a   Watanabe, T ^b   Minami, H ^c   Aogi, K ^d   Tabei, T ^e   Sano, M ^f   Masuda, N ^g   Andoh, J ^h   Ikeda, T ⁱ   Shibata, T ^j   Takashima, S ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Hamamatsu Oncology Center   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f Niigata Breast Exam Center   (Japan)

^g OSAKA NATIONAL HOSPITAL   (Japan)

^h TOCHIGI CANCER CENTER   (Japan)

ⁱ TEIKYO UNIVERSITY HOSPITAL   (Japan)

^j NATIONAL CANCER CENTER   (Japan)

more..

Author keywords

Cyclophosphamide; Docetaxel; Doxorubicin; Metastatic breast cancer; Phase III

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA;

EID: 67650364332     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn781     Document Type: Article

References (14)

1. Gennari A, Conte P, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104: 1742-1750.
2. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
3. Nabholtz JM, Falkson C, Campos D et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21: 968-975.
4. Mackey JR, Paterson A, Dirix L, Dewar J. Final results of the phase III randomised trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21: 35a (Abstr 137).
5. Bontenbal M, Creemers GJ, Braun HJ et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005; 23: 7081-7088.
6. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1733.
7. Evans WK, Feld R, Murray N et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987; 107: 451-458.
8. Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855-861.
9. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104: 739-746.
10. Adachi I, Watanabe T, Takashima S et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73: 210-216.
11. Tobinai K, Kohno A, Shimada Y et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250-257.
12. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26: 1980-1986.
13. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005; 93: 293-301.
14. Harvey V, Mouridsen H, Semiglazov V et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24: 4963-4970.